Literature DB >> 1425410

Role of luteinizing hormone in the expression of cholesterol side-chain cleavage cytochrome P450 and 3 beta-hydroxysteroid dehydrogenase, delta 5-4 isomerase messenger ribonucleic acids in the primate corpus luteum.

N Ravindranath1, L Little-Ihrig, D F Benyo, A J Zeleznik.   

Abstract

It is well established that LH has an obligatory role in the acute production of progesterone by the primate corpus luteum in vivo because interruption of LH support to the corpus luteum at any time during the luteal phase is accompanied by an immediate and sustained fall in serum progesterone concentrations. However, recent studies have demonstrated that maximal steroidogenic capacity of cultured human luteal cells and maximal levels of messenger RNAs (mRNAs) for cholesterol side chain cleavage cytochrome P450 (P450scc) and 3 beta-hydroxysteroid dehydrogenase, delta 5-4 isomerase (3 beta-HSD) in luteal tissue are observed shortly after luteinization and decline thereafter throughout the remainder of the luteal phase. These findings would suggest that the role of LH in the acute regulation of progesterone production may differ from its role in the expression of mRNAs for steroidogenic enzymes. We initiated the current studies to define the role of LH upon the expression of mRNAs for P450scc and 3 beta-HSD by the primate corpus luteum. For this purpose, we treated cynomolgus monkeys with a potent GnRH antagonist for 1, 2, and 3 days during the luteal phase of the menstrual cycle and measured levels of mRNAs for P450scc and 3 beta-HSD in corpora lutea. Treatment of monkeys with the GnRH antagonist reduced bioactive LH concentrations to less than 5 ng/ml by 48 h of treatment, and LH concentrations remained less than 5 ng/ml thereafter. Serum progesterone concentrations were reduced by 74% after 1 day of antagonist treatment, 88% after 2 days of antagonist treatment, and by more than 95% after 3 days of GnRH antagonist treatment. Although progesterone secretion was markedly diminished after 24 h of antagonist treatment, there were no differences in mRNAs for P450scc and 3 beta-HSD between antagonist-treated and control animals. However, mRNAs for P450scc and 3 beta-HSD were significantly (P < 0.05) reduced after 2 days of antagonist treatment and were nearly nondetectable after 3 days of antagonist treatment. These results demonstrate a temporal dissociation of the effects of LH on the acute regulation of progesterone secretion and the maintenance of specific mRNAs involved in progesterone production. Nonetheless, the results clearly show that LH is required for the continued expression of mRNAs for P450scc and 3 beta-HSD by the primate corpus luteum.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1425410     DOI: 10.1210/endo.131.5.1425410

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  5 in total

1.  The effect of leuprorelin on steroidogenesis of human preovulatory granulosa cells in vitro.

Authors:  R Fabbri; E Porcu; A Pession; E Sereni; T Marsella; R Seracchioli; C Flamigni
Journal:  J Assist Reprod Genet       Date:  1996-04       Impact factor: 3.412

2.  In vivo responses of the primate corpus luteum to luteinizing hormone and chorionic gonadotropin.

Authors:  A J Zeleznik
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

Review 3.  Environmental toxicant exposure and menstrual cycle length.

Authors:  Karissa C Hammer; Alexis Veiga; Shruthi Mahalingaiah
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2020-12       Impact factor: 3.626

Review 4.  Cholesterol transport and steroidogenesis by the corpus luteum.

Authors:  Lane K Christenson; Luigi Devoto
Journal:  Reprod Biol Endocrinol       Date:  2003-11-10       Impact factor: 5.211

5.  Hormone and prostaglandin F2 alpha regulation of messenger ribonucleic acid encoding steroidogenic acute regulatory protein in human corpora lutea.

Authors:  P H Chung; T W Sandhoff; M P McLean
Journal:  Endocrine       Date:  1998-04       Impact factor: 3.925

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.